Historical Stock Chart
3 Months : From Oct 2019 to Jan 2020
By Adria Calatayud
AstraZeneca PLC (AZN.LN) said Monday that its Imfinzi drug achieved positive results in a phase 3 trial in previously-untreated metastatic non-small cell lung cancer.
The U.K. pharmaceutical company said the trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final progression-free survival analysis in patients treated with a combination of Imfinzi and five standard-of-care platinum-based chemotherapy options versus chemotherapy alone.
The triple combination of Imfinzi plus tremelimumab and chemotherapy also demonstrated a statistically significant and clinically meaningful PFS improvement versus chemotherapy alone as a key secondary endpoint, AstraZeneca said.
The company said both Imfinzi and Imfinzi plus tremelimumab delayed disease progression in a phase 3 study for first-line treatment of metastatic non-small cell lung cancer.
The trial will continue to assess the additional primary endpoint of overall survival with data anticipated in 2020, AstraZeneca said.
Shares in London at 1544 GMT were up 2.1% at 7,536 pence.
Write to Adria Calatayud at email@example.com
(END) Dow Jones Newswires
October 28, 2019 12:05 ET (16:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.